Literature DB >> 17403977

Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.

Romina Mizrahi1, Pablo Rusjan, Ofer Agid, Ariel Graff, David C Mamo, Robert B Zipursky, Shitij Kapur.   

Abstract

OBJECTIVES: Antipsychotic medications improve psychosis but often induce a state of dysphoria in patients. Blockade of the dopamine D(2) receptors, which is thought to mediate their efficacy, has also been implicated in producing this adverse subjective experience. The authors present the first double-blind controlled study to examine the relationship between striatal and extrastriatal dopamine D(2) receptor binding potential and occupancy values and adverse subjective experience.
METHOD: Patients with recent-onset psychosis (N=12) were randomly assigned to low or high doses of olanzapine or risperidone. Subjective experiences, motor side effects, and striatal and extrastriatal dopamine D(2) receptors (determined with [(11)C]raclopride and [(11)C]FLB 457 PET scans, respectively) were evaluated after 2 weeks of continuous antipsychotic treatment.
RESULTS: Higher dopamine D(2) receptor occupancy and binding potentials in the striatal (dorsal and ventral), temporal, and insular regions were associated with subjective experience. The finding was confirmed with two convergent methods of analysis (region-of-interest and voxel-based statistics), and the same relationship was observed using two different dopamine receptor measures (observed binding potential values and age- and sex-corrected occupancy values).
CONCLUSIONS: Higher D(2) receptor occupancy is associated with negative subjective experience in patients taking risperidone or olanzapine. These negative subjective effects may be related to the high discontinuation rates seen in usual practice. Understanding the neurobiological mechanism of these negative subjective experiences and developing antipsychotics with novel (i.e., non D(2)) mechanisms may be critical in improving the treatment of psychosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17403977     DOI: 10.1176/ajp.2007.164.4.630

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  33 in total

Review 1.  Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.

Authors:  Selene R T Veerman; Peter F J Schulte; Lieuwe de Haan
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 2.  Classifying antipsychotic agents : need for new terminology.

Authors:  Ripu D Jindal; Matcheri S Keshavan
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  Preliminary data indicating a connection between stress-induced prefrontal dopamine release and hippocampal TSPO expression in the psychosis spectrum.

Authors:  Christin Schifani; Sina Hafizi; Huai-Hsuan Tseng; Cory Gerritsen; Miran Kenk; Alan A Wilson; Sylvain Houle; Pablo M Rusjan; Romina Mizrahi
Journal:  Schizophr Res       Date:  2018-11-06       Impact factor: 4.939

4.  Antipsychotics and amotivation.

Authors:  Gagan Fervaha; Hiroyoshi Takeuchi; Jimmy Lee; George Foussias; Paul J Fletcher; Ofer Agid; Gary Remington
Journal:  Neuropsychopharmacology       Date:  2015-01-08       Impact factor: 7.853

5.  DRD2 polymorphisms modulate reward and emotion processing, dopamine neurotransmission and openness to experience.

Authors:  Marta Peciña; Brian J Mickey; Tiffany Love; Heng Wang; Scott A Langenecker; Colin Hodgkinson; Pei-Hong Shen; Sandra Villafuerte; David Hsu; Sara L Weisenbach; Christian S Stohler; David Goldman; Jon-Kar Zubieta
Journal:  Cortex       Date:  2012-02-14       Impact factor: 4.027

6.  The relationship between excitement symptom severity and extrastriatal dopamine D2/3 receptor availability in patients with schizophrenia: a high-resolution PET study with [18F]fallypride.

Authors:  Yo-Han Joo; Jeong-Hee Kim; Young-Don Son; Hang-Keun Kim; Yeon-Jeong Shin; Sang-Yoon Lee; Jong-Hoon Kim
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-06-16       Impact factor: 5.270

7.  Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia.

Authors:  Sarah A Eisenstein; Ryan Bogdan; Ling Chen; Stephen M Moerlein; Kevin J Black; Joel S Perlmutter; Tamara Hershey; Deanna M Barch
Journal:  J Psychiatr Res       Date:  2016-11-17       Impact factor: 4.791

Review 8.  Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis.

Authors:  William A Carlezon; Mark J Thomas
Journal:  Neuropharmacology       Date:  2008-07-15       Impact factor: 5.250

9.  Model-based parametric study of frontostriatal abnormalities in schizophrenia patients.

Authors:  Shoji Tanaka
Journal:  BMC Psychiatry       Date:  2010-02-27       Impact factor: 3.630

10.  Dopamine D2 receptor occupancy levels of acute sulpiride challenges that produce working memory and learning impairments in healthy volunteers.

Authors:  Mitul A Mehta; Andrew J Montgomery; Yuri Kitamura; Paul M Grasby
Journal:  Psychopharmacology (Berl)       Date:  2007-10-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.